La cadena de opciones muestra datos clave de las opciones de acciones de Intensity Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Intensity Therapeutics..

Intensity Therapeutics (NASDAQ:INTS) Bolsa, Cadena de Opciones

Intensity Therapeutics

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics Inc

Apollomics Inc. - Class A Ordinary Shares

Apollomics

Apimeds Pharmaceuticals US, Inc. Common Stock

Apimeds Pharmaceuticals

AlphaTON Capital

Boundless Bio

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies

Dyadic International, Inc. - Common Stock

Dyadic International

Generation Bio

iBio

Klotho Neurosciences, Inc. - Common Stock

Klotho Neurosciences

Liminatus Pharma, Inc. - Class A Common Stock

Liminatus Pharma

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

Nanoviricides

NeuroSense Therapeutics Ltd. - Ordinary Shares

NeuroSense Therapeutics

NextCure

Pluri

Q32 Bio

Radiopharm Theranostics Limited - American Depositary Shares

Radiopharm Theranostics

Rallybio

RenovoRx

SAB Biotherapeutics

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Tenax Therapeutics

Tharimmune

Exicure

Intensity Therapeutics (INTS) Previsión

Noticias

Beneficios

Calificaciones de analistas

Interés en corto

Informe de acciones

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.

Comments

Intensity Therapeutics Cadena de Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL